Every 8-K that GoHealth, Inc. (GOCO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow GOCO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GOCO filings page.
GoHealth, Inc. announced that Nasdaq will delist its Class A common stock after the company and affiliates filed voluntary Chapter 11 cases to implement a prepackaged reorganization plan. Nasdaq cited the bankruptcy filings, concerns about residual equity value, and prior noncompliance with the $35 million minimum market value rule.
Trading on Nasdaq is scheduled to be suspended at the opening on June 16, 2026, after which a Form 25-NSE will remove the stock from Nasdaq listing and registration. GoHealth will not appeal the decision and expects no impact on its ongoing business operations or the Chapter 11 process.
The company anticipates its shares may be quoted on an over-the-counter market, but warns that these markets are more limited and could reduce liquidity. GoHealth cautions that trading in its Class A common stock during the Chapter 11 cases is highly speculative and that market prices may bear little or no relationship to any ultimate recovery for existing shareholders.
GoHealth, Inc. has filed voluntary, prepackaged Chapter 11 cases in Delaware to implement a restructuring plan supported by 100% of its lenders, over 60% of Class A stockholders and over 99% of GoHealth Holdings unitholders. The company expects to operate as normal during the process.
Under the proposed plan, all existing equity interests other than Series A redeemable convertible preferred stock will be canceled, with eligible Class A stockholders and GoHealth Holdings unitholders sharing a $10.0 million cash equity recovery pool. The plan will transfer ownership to certain lenders and result in a change of control if confirmed.
GoHealth expects its Class A common stock to be delisted from Nasdaq, with trading likely moving to an over-the-counter market. The company warns that trading in its shares during the Chapter 11 process is highly speculative and that trading prices may not reflect ultimate recoveries for equity holders.
GoHealth, Inc. reported a sharp downturn in full-year 2025 results as it intentionally pulled back Medicare Advantage activity in a tougher market. Net revenues fell to $361.8 million, down 54.7% from 2024, while the company posted a net loss of $497.8 million, including $260.0 million of asset impairment charges.
Adjusted EBITDA swung from a $120.3 million profit in 2024 to a $35.1 million loss, and operating cash flow was a negative $121.9 million. Management emphasized a consumer-first strategy, higher retention, focus on Special Needs Plans, and targeted AI investments to lower acquisition costs and prepare for future industry consolidation.
GoHealth, Inc. reported that Nasdaq has notified the company it is not in compliance with Nasdaq Listing Rule 5550(b)(2), which requires a minimum market value of listed securities of $35 million. The notice also states GoHealth does not meet the alternative standards of at least $2.5 million in stockholders’ equity or $500,000 in net income from continuing operations.
The company’s shares will continue trading on The Nasdaq Global Market under the symbol GOCO while it has 180 calendar days, until September 14, 2026, to regain compliance. If compliance is not restored, Nasdaq may move to delist the stock, though GoHealth could appeal to a Nasdaq Hearings Panel. The company is evaluating options to regain compliance but cautions there is no assurance it will succeed.
GoHealth, Inc. filed a current report to let investors know it has released its latest quarterly financial results. On November 13, 2025, the company issued a press release announcing results for the quarter ended September 30, 2025, and furnished that press release as Exhibit 99.1 to this report. The company notes that this earnings information is being furnished rather than filed, which means it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities filings unless specifically referenced.
GoHealth, Inc. reported several changes to its Board of Directors. On August 19, 2025, the Board appointed Mark Weinsten as a Class II director, with a term running until the 2028 annual stockholders’ meeting. He is a managing director in BRG Corporate Finance and will receive a monthly cash retainer of $25,000, pro-rated for his first partial month, plus reimbursement of certain expenses.
The Board also appointed Bao Truong, a senior managing director at Centerbridge Partners, L.P., as a Class III director with a term expiring at the 2026 annual stockholders’ meeting. He joined the Transformation Committee, Compensation Committee, and Nominating and Corporate Governance Committee and, as a Centerbridge employee, will not receive Board compensation. Both new directors entered into GoHealth’s standard director indemnification agreements, and each was nominated as a Centerbridge designee under a 2020 Stockholders Agreement.
On the same date, Centerbridge designees Jeremy W. Gelber and Abhiraj Modi resigned from the Board. The company stated their resignations did not result from any disagreement regarding operations, policies, or practices.
On 6 Aug 2025, GoHealth (GOCO) executed a series of financing and governance actions aimed at improving near-term liquidity and extending maturities.
- $115 m super-priority term loan: $80 m in new money ($40 m funded now; $40 m delayed-draw before Dec-25) plus $35 m roll-up of existing revolver. Rate: Term SOFR + 5.50 % (3 % floor) or ABR + 4.50 % (4 % floor) plus a cash MOIC premium of up to 2.0×. Maturity: 5 Aug 2029. First-lien on substantially all assets and senior to the existing credit facility.
- Covenants: Weekly minimum liquidity starts at $5 m (Oct-25) and rises to $30 m (Sep-26). Borrower barred from prepaying legacy Class A loans until super-priority debt is fully repaid.
- Amendment No. 14: Terminates unused revolver commitments, extends remaining Class A revolver maturity to 2029, allows part PIK interest (Adj. SOFR + 8 %) and waives term-loan amortization until 31 Dec 2026. Leverage and asset coverage covenants removed.
- Equity issuance: Lenders received 4,766,219 Class A shares (~19.99 % of pre-transaction shares) in a private placement.
- Board changes: Three directors appointed (Timothy R. Pohl, Alan J. Carr, William L. Transier); three directors resigned. A new Transformation Committee will evaluate strategic alternatives.
The package provides fresh capital and maturity relief but at high cost and with substantial dilution and restrictive covenants.
GoHealth (Nasdaq: GOCO) filed an 8-K disclosing the results of its 2025 Annual Meeting of Stockholders held on June 18, 2025.
Shareholders elected three Class II directors—Brandon M. Cruz (17,218,021 FOR), Alan Wheatley (17,932,740 FOR) and Abhiraj R. Modi (17,619,537 FOR)—to serve until the 2028 meeting. Ernst & Young LLP was ratified as independent auditor with 21,544,738 FOR and only 557,922 AGAINST. The non-binding say-on-pay resolution passed (17,026,293 FOR; 992,227 AGAINST), and shareholders approved an amendment to the 2020 Incentive Award Plan (16,755,619 FOR; 1,287,341 AGAINST).
No financial performance metrics, strategic updates, or other material events were included in the filing.